marine drugs

IMPACT FACTOR 5.4 | Indexed in: PubMed | CITESCORE 9.6

an Open Access Journal by MDPI

Marine Biotoxins

Guest Editor:

Prof. Dr. Jordi Molgó
CEA, INRAE, Institut des Sciences du Vivant Frédéric Joliot, Département Médicaments et Technologies pour la Santé (DMTS), Equipe Mixte de Recherche CNRS n° 9004, Service d'Ingénierie Moléculaire pour la Santé (SIMoS), Université Paris-Saclay, Bâtiment 152, rue de la Biologie, Point courrier 24, F-91191 Gif sur Yvette, France

Deadline for manuscript submissions:
closed (16 October 2021)

Message from the Guest Editor

Marine environments are known to contain microorganisms such as bacteria, cyanobacteria, dinoflagellates, diatoms, and fungi. When environmental conditions are favorable for their massive proliferation, these unicellular microorganisms may manifest their potential toxicity by producing marine biotoxins and contaminating invertebrate and vertebrate marine organisms through the food web.

This special issue of Marine Drugs is open to original research articles and reviews dealing with marine biotoxins and the following subjects: 1. Identification of new and emergent marine biotoxins. 2. Marine biotoxins from identified bacteria, cyanobacteria, fungi, dinoflagellates, and diatoms. 3. Characterization of new biotoxin chemical structures. 4. Biosynthetic pathways involved in biotoxin production. 5. Cellular and molecular signaling pathways implicated in marine biotoxin action. 6. Pharmacology and structure–activity relationship. 7. Bio-distribution, metabolism, acute and chronic toxicity in animal models. 8. Molecular modeling of marine biotoxins with their putative receptors. 9. Potential therapeutic uses of marine biotoxins.

marine drugs

IMPACT FACTOR 5.4 | Indexed in: PubMed | CITESCORE 9.6

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker
Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.
Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmacology, Toxicology and Pharmaceutics (miscellaneous)*)

Contact Us

Marine Drugs Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
𝕏@Marine_Drugs